Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas.

Zikou A, Sioka C, Alexiou GA, Fotopoulos A, Voulgaris S, Argyropoulou MI.

Contrast Media Mol Imaging. 2018 Dec 2;2018:6828396. doi: 10.1155/2018/6828396. eCollection 2018. Review.

2.

Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.

Liu ZC, Yan LF, Hu YC, Sun YZ, Tian Q, Nan HY, Yu Y, Sun Q, Wang W, Cui GB.

BMC Med Imaging. 2017 Feb 1;17(1):10. doi: 10.1186/s12880-017-0183-y.

3.

Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.

Kong Z, Yan C, Zhu R, Wang J, Wang Y, Wang Y, Wang R, Feng F, Ma W.

Neuroimage Clin. 2018 Jul 5;20:51-60. doi: 10.1016/j.nicl.2018.07.001. eCollection 2018. Review.

4.

Post-treatment imaging of high-grade gliomas.

Sanghvi D.

Indian J Radiol Imaging. 2015 Apr-Jun;25(2):102-8. doi: 10.4103/0971-3026.155829.

5.

New advances that enable identification of glioblastoma recurrence.

Yang I, Aghi MK.

Nat Rev Clin Oncol. 2009 Nov;6(11):648-57. doi: 10.1038/nrclinonc.2009.150. Epub 2009 Oct 6. Review.

PMID:
19806145
6.

Comparison of Diffusion Tensor Imaging and Magnetic Resonance Perfusion Imaging in Differentiating Recurrent Brain Neoplasm From Radiation Necrosis.

Masch WR, Wang PI, Chenevert TL, Junck L, Tsien C, Heth JA, Sundgren PC.

Acad Radiol. 2016 May;23(5):569-76. doi: 10.1016/j.acra.2015.11.015. Epub 2016 Feb 23.

7.

Advanced magnetic resonance imaging in glioblastoma: a review.

Shukla G, Alexander GS, Bakas S, Nikam R, Talekar K, Palmer JD, Shi W.

Chin Clin Oncol. 2017 Aug;6(4):40. doi: 10.21037/cco.2017.06.28. Review.

8.

Comparison of diffusion tensor, dynamic susceptibility contrast MRI and (99m)Tc-Tetrofosmin brain SPECT for the detection of recurrent high-grade glioma.

Alexiou GA, Zikou A, Tsiouris S, Goussia A, Kosta P, Papadopoulos A, Voulgaris S, Tsekeris P, Kyritsis AP, Fotopoulos AD, Argyropoulou MI.

Magn Reson Imaging. 2014 Sep;32(7):854-9. doi: 10.1016/j.mri.2014.04.013. Epub 2014 Apr 24.

PMID:
24848292
9.

Pseudoprogression in high-grade glioma.

Knudsen-Baas KM, Moen G, Fluge Ø, Storstein A.

Acta Neurol Scand Suppl. 2013;(196):31-7. doi: 10.1111/ane.12047. Review. Erratum in: Acta Neurol Scand Suppl. 2013 Mar;127(3):e17.

PMID:
23190289
10.

Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum--use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI.

Fatterpekar GM, Galheigo D, Narayana A, Johnson G, Knopp E.

AJR Am J Roentgenol. 2012 Jan;198(1):19-26. doi: 10.2214/AJR.11.7417. Review.

PMID:
22194475
11.

Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.

Thomas AA, Arevalo-Perez J, Kaley T, Lyo J, Peck KK, Shi W, Zhang Z, Young RJ.

J Neurooncol. 2015 Oct;125(1):183-90. doi: 10.1007/s11060-015-1893-z. Epub 2015 Aug 15.

12.

Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.

Choi YJ, Kim HS, Jahng GH, Kim SJ, Suh DC.

Acta Radiol. 2013 May;54(4):448-54. doi: 10.1177/0284185112474916. Epub 2013 Apr 30.

PMID:
23592805
13.

Advanced MRI Techniques in the Monitoring of Treatment of Gliomas.

Hyare H, Thust S, Rees J.

Curr Treat Options Neurol. 2017 Mar;19(3):11. doi: 10.1007/s11940-017-0445-6. Review.

PMID:
28349351
14.
15.

Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.

Chaskis C, Neyns B, Michotte A, De Ridder M, Everaert H.

Surg Neurol. 2009 Oct;72(4):423-8. doi: 10.1016/j.surneu.2008.09.023. Epub 2009 Jan 15.

PMID:
19150114
16.

Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.

Huang RY, Neagu MR, Reardon DA, Wen PY.

Front Neurol. 2015 Feb 23;6:33. doi: 10.3389/fneur.2015.00033. eCollection 2015. Review.

17.

Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.

Topkan E, Topuk S, Oymak E, Parlak C, Pehlivan B.

Am J Clin Oncol. 2012 Jun;35(3):284-9. doi: 10.1097/COC.0b013e318210f54a.

PMID:
21399487
18.

Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.

Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B.

Radiat Oncol. 2013 Feb 20;8:38. doi: 10.1186/1748-717X-8-38.

19.

Perfusion MRI in treatment evaluation of glioblastomas: Clinical relevance of current and future techniques.

van Dijken BRJ, van Laar PJ, Smits M, Dankbaar JW, Enting RH, van der Hoorn A.

J Magn Reson Imaging. 2019 Jan;49(1):11-22. doi: 10.1002/jmri.26306.

PMID:
30561164
20.

Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.

Yun TJ, Park CK, Kim TM, Lee SH, Kim JH, Sohn CH, Park SH, Kim IH, Choi SH.

Radiology. 2015 Mar;274(3):830-40. doi: 10.1148/radiol.14132632. Epub 2014 Oct 21.

PMID:
25333475

Supplemental Content

Support Center